SVF
Level D· Preclinical EvidenceAnimal Study

Transcriptomic and functional comparison of adipose-and bone marrow-derived mesenchymal stem cells for tendon regeneration.

Khaled H., Zayed M., Kim B., Jeong BH., Oh SI.

Animal Study on Tendon Injury, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
PMID
41957779
DOI
10.1186/s13287-026-04961-2

Abstract (original English)

Tendons are specialized connective tissues with limited intrinsic healing properties due to hypovascularity and low metabolic activity. Mesenchymal stem cells (MSCs) possess regenerative potential for tendon injuries. Among the diverse sources of MSCs, those derived from the bone marrow (BM-MSCs) and adipose tissue (AD-MSCs) are the leading candidates. However, their relative efficacy remains underexplored, particularly in terms of biological characteristics and tenogenic differentiation. In addition, the signaling pathways driving tenogenic differentiation processes remain poorly understood. This study aimed to comprehensively investigate the regenerative potential of AD-MSCs and BM-MSCs for tendon repair. AD- and BM-MSCs were isolated from rats and evaluated for stemness based on morphology, viability, immunophenotyping, and tri-lineage differentiation. RNA sequencing was performed to obtain a baseline molecular profile of each MSC type prior to tenogenic differentiation. We evaluated the potential of AD- and BM-MSCs to differentiate into tendon-like cells in vitro using gene expression and immunofluorescence. A rat model of Achilles tendon injury was created to evaluate the regenerative efficacy following each MSC-type injection. After 6 weeks, tendon regeneration was assessed using histological and immunohistochemical analyses. Both MSCs displayed similarities in morphology

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsMesenchymal Stem CellsRatsAdipose TissueRegenerationBone Marrow CellsCell DifferentiationTendon InjuriesTranscriptomeRats, Sprague-Dawley
Ankle & FootTendon Injury
View on PubMedDOI

Related research